Key result
Direct oral anticoagulants were associated with equal stroke severity and 3-month clinical outcomes compared to vitamin K antagonists in patients with acute ischemic stroke, despite older age.
Why the study?
The study aimed to compare outcomes between acute ischemic stroke patients receiving vitamin K antagonists and those receiving direct oral anticoagulants.
Do direct oral anticoagulants compared to vitamin K antagonists result in different stroke severity and 3-month clinical outcomes in patients experiencing acute ischemic stroke despite regular anticoagulation?
Cross-Sectional (n=135)
No
Do direct oral anticoagulants compared to vitamin K antagonists result in different stroke severity and 3-month clinical outcomes in patients experiencing acute ischemic stroke despite regular anticoagulation?
In patients who experience an acute ischemic stroke despite regular anticoagulation, prior use of DOACs is associated with comparable stroke severity and 3-month clinical outcomes to prior use of VKAs.
No takes yet. Share an insight, caveat, or question.
Supports comparable outcomes with DOACs versus VKAs in breakthrough strokes; leaves open randomized confirmation in anticoagulated patients.
Çakmak et al. (2024) conducted a cross-sectional in Acute ischemic stroke (n=135). Direct oral anticoagulants (DOACs) vs. Vitamin K antagonist (VKA) was evaluated on Stroke severity and 3-month clinical outcomes. Direct oral anticoagulants were associated with equal stroke severity and 3-month clinical outcomes compared to vitamin K antagonists in patients with acute ischemic stroke, despite older age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: